Cone-Rod Degeneration

Cone-rod degeneration (also called cone-rod dystrophy) is a rare, inherited eye disease that slowly damages the light-sensitive cells (photoreceptors) in the retina. First, the cone cells in the center of the retina stop working well, so color vision, sharp central vision, and seeing in bright light get worse. Later, the rod cells around the edges are also damaged, so side vision and night vision slowly go down. There is no cure yet. Treatment today mainly supports the remaining vision, treats problems like retinal swelling or glaucoma, and helps people live safely and independently with low vision.

Cone-rod degeneration, more often called cone-rod dystrophy (CRD), is a rare inherited eye disease in which the light-sensing cells in the retina slowly stop working. The cones are damaged first, so problems usually start with day vision, color vision, glare, and sharp central vision. Later, the rods also become damaged, so night vision and side vision get worse too. The retina is the thin light-sensitive layer at the back of the eye, and when cone and rod cells degenerate, the brain receives a weaker and less clear picture. In simple words, this disease causes the eye to slowly lose the cells that help a person see clearly in bright light and dim light. [MedlinePlus Genetics]

Cone-rod degeneration is usually genetic, which means it happens because of a change in a gene that helps the retina work normally. It can appear in childhood, teenage years, or adulthood, depending on the gene and the person. Doctors place it under a larger group called inherited retinal diseases. In many patients, the condition affects both eyes and usually gets worse slowly over time. Some people lose vision early, while others keep useful vision for many years. [Orphanet]

Because cone-rod degeneration is usually caused by gene changes, it often runs in families. Symptoms may start in childhood, the teenage years, or early adult life. Common problems include light sensitivity, needing more light to read, colors looking washed out, and bumping into things in dim light. Over many years, vision can become severely reduced, but the condition is not painful and is not life-threatening. Genetic counseling, low-vision care, and good eye-safety habits are very important parts of management.

Other names for cone-rod degeneration include cone-rod dystrophy, CRD, CORD, inverse retinitis pigmentosa, and sometimes central or inverse retinal dystrophy in older descriptions. These names are used because the disease often begins with cone loss first and then later involves the rods, which is the opposite pattern of typical retinitis pigmentosa. [NCBI Bookshelf]

Types

Doctors describe cone-rod degeneration in different ways. One common way is by inheritance pattern. The main inherited types are: autosomal recessive cone-rod degeneration, autosomal dominant cone-rod degeneration, and X-linked cone-rod degeneration. Autosomal recessive disease often means a child receives one changed gene from each parent. Autosomal dominant disease can happen when one changed copy is enough to cause disease. X-linked disease involves a gene on the X chromosome and often affects males more severely. [MedlinePlus Genetics]

Another way to describe types is by clinical pattern. Doctors may speak of early-onset cone-rod degeneration, adult-onset cone-rod degeneration, isolated or nonsyndromic cone-rod degeneration, and syndromic cone-rod degeneration. “Nonsyndromic” means the eye disease happens mostly by itself. “Syndromic” means the retinal disease appears together with problems in other body systems, such as hearing, brain, bone, or growth disorders. [Orphanet]

Causes

The true root cause of cone-rod degeneration is usually a gene mutation that harms the structure or function of photoreceptor cells, the retinal pigment epithelium, or the visual cycle. Below are 20 recognized genetic causes or cause groups that have been linked to cone-rod degeneration in medical genetics sources. [MedlinePlus Genetics]

1. ABCA4 gene changes are one of the best-known causes, especially in autosomal recessive disease. This gene helps move vitamin A–related molecules inside photoreceptor cells. When it does not work well, toxic by-products build up and damage the retina. [MedlinePlus Genetics]

2. CRX gene changes can cause cone-rod degeneration by disturbing retinal development and photoreceptor gene control. CRX is a very important retinal transcription factor, so a defect can strongly affect cone and rod survival. [MedlinePlus Genetics]

3. GUCA1A gene changes can lead to abnormal calcium signaling inside photoreceptors. This harms cone function early and may later affect rods too. [MedlinePlus Genetics PDF gene list]

4. GUCY2D gene changes can impair the recovery phase of photoreceptors after light stimulation. This can produce severe cone disease and later rod involvement. [MedlinePlus Genetics PDF gene list]

5. RPGR gene changes are an important cause of X-linked inherited retinal degeneration and can produce cone-rod patterns in some families. These changes disturb transport inside photoreceptor cilia. [NCBI Bookshelf; NEI]

6. RPGRIP1 gene changes can damage the connection and signaling system of photoreceptor cells, leading to progressive retinal degeneration. [MedlinePlus Genetics PDF gene list]

7. PROM1 gene changes may injure the outer segment structure of photoreceptors, causing loss of visual sharpness and color vision over time. [MedlinePlus Genetics PDF gene list]

8. RIMS1 gene changes can affect synaptic signaling in the retina. Because retinal cells must pass light signals with great precision, disruption can gradually reduce vision. [MedlinePlus Genetics PDF gene list]

9. PITPNM3 gene changes have been reported in some inherited families with cone-rod dystrophy. These changes likely disturb retinal cell membrane signaling. [MedlinePlus Genetics PDF gene list]

10. RAX2 gene changes may interfere with retinal gene regulation and photoreceptor maintenance, which can lead to progressive cone-first degeneration. [MedlinePlus Genetics PDF gene list]

11. DRAM2 gene changes can impair retinal cell survival and are linked with inherited retinal degeneration, including cone-rod patterns in some patients. [MedlinePlus Genetics PDF gene list]

12. POC1B gene changes can cause structural problems in photoreceptor cilia, which are tiny parts of the cell that are essential for normal vision. [MedlinePlus Genetics PDF gene list]

13. RAB28 gene changes may disturb transport pathways inside retinal cells. Over time, this can damage photoreceptors and reduce central and color vision. [MedlinePlus Genetics PDF gene list]

14. SEMA4A gene changes can affect retinal support functions and may contribute to degeneration of both cones and rods. [MedlinePlus Genetics PDF gene list]

15. TTLL5 gene changes can disrupt proteins important for photoreceptor function, especially in cone-dominant disease that later spreads to rods. [MedlinePlus Genetics PDF gene list]

16. TULP1 gene changes can interfere with protein trafficking in photoreceptors. This can produce severe inherited retinal degeneration, including cone-rod disease. [MedlinePlus Genetics PDF gene list]

17. UNC119 gene changes may disturb photoreceptor transport and survival, leading to progressive retinal dysfunction. [MedlinePlus Genetics PDF gene list]

18. KCNV2-related disease can create a cone-dominant disorder with unusual electrical test findings and later broader retinal dysfunction. [MedlinePlus Genetics PDF gene list; electrophysiology review]

19. Ciliary dysfunction in general is a major cause group. Many inherited retinal diseases happen because the photoreceptor cilium does not transport materials correctly, and this slowly kills the cells. [Approach to inherited retinal diseases]

20. Syndromic genetic disorders, such as some neurologic, skeletal, or multisystem inherited diseases, can also include cone-rod degeneration as one feature. In these patients, the same genetic problem harms both the retina and other organs. [Orphanet review]

Symptoms

1. Blurred central vision is one of the earliest symptoms. A person may say that faces, books, or phone text look unclear even with glasses. This happens because cones are concentrated in the macula, the center of the retina. [NCBI Bookshelf]

2. Reduced visual acuity means vision becomes less sharp. People may notice that they cannot read the eye chart as well as before. This often slowly worsens over time. [Orphanet]

3. Photophobia means strong sensitivity to light. Bright sunlight, white screens, or indoor glare may feel uncomfortable or painful because damaged cones handle bright light poorly. [MedlinePlus Genetics]

4. Glare disability means a person can see even less when there is bright reflection from lights, shiny floors, or car headlights. This is a common daily problem in cone disease. [AAO guidance on inherited retinal disease assessment]

5. Poor color vision is very common. Colors may look faded, mixed up, or hard to identify, especially red-green differences or more general color discrimination loss. [MedlinePlus Genetics]

6. Trouble reading happens because reading needs good central vision, contrast, and stable fixation. Even when large objects are visible, small print becomes difficult. [NCBI Bookshelf]

7. Central scotoma means a blind or weak spot in the center of vision. A person may look directly at something and still not see its middle clearly. [IOVS summary]

8. Night blindness or poor seeing in dim light often appears later, after the rods become involved. This can make walking outside at dusk or moving around a dark room difficult. [MedlinePlus Genetics; NCBI Bookshelf]

9. Loss of side vision may develop as rod damage becomes worse. At first this may be mild, but later a person may bump into objects or miss movement off to the side. [NCBI Bookshelf]

10. Slow light adaptation means the eyes take longer to adjust when moving between bright and dark places. This reflects reduced photoreceptor function. [Webvision electrophysiology review]

11. Reduced contrast sensitivity means it becomes hard to see light objects on light backgrounds or dark objects on dark backgrounds. Many patients describe this as “washed out” vision. [Approach to inherited retinal diseases]

12. Difficulty recognizing faces can happen because this job depends on fine central vision and contrast. People may recognize voices before faces. [NCBI Bookshelf]

13. Nystagmus can happen in some early or severe cases. This means the eyes make small, repeated movements that are hard to control. [Orphanet related retinal dystrophy descriptions; OMIM summary]

14. Visual field defects are areas where vision is missing or weaker. These defects may begin centrally and then spread depending on disease stage. [IOVS summary]

15. Progressive vision loss is the overall symptom pattern. The disease usually does not stay the same. Instead, vision slowly becomes worse over years, though the speed is different from person to person. [Orphanet; review article]

Diagnostic Tests

The diagnosis of cone-rod degeneration is usually made by combining history, eye examination, retinal imaging, electrical testing, and genetic testing. No single test tells the full story in every patient. Doctors use several tests together to understand which retinal cells are affected, how advanced the disease is, and which gene may be responsible. [Review article]

1. History taking. The doctor asks about blurred central vision, light sensitivity, color trouble, night blindness, family history, age at onset, and how fast the vision has changed. This is important because cone-first symptoms strongly suggest this diagnosis. [Review article]
2. Visual acuity test. This checks how clearly the person can see letters at a set distance. Cone-rod degeneration often causes early loss of sharp vision because cones are needed for detailed central sight. [Orphanet/OMIM summaries]
3. Pupil examination. The clinician looks at pupil size and light reaction. This test does not diagnose cone-rod degeneration alone, but it helps rule out other eye or nerve problems and forms part of a complete eye exam. [AAO guidance]
4. Slit-lamp examination. This microscope exam checks the front of the eye for other problems, such as cataract or corneal disease, that could also reduce vision. It helps make sure the vision loss is really from the retina. [AAO guidance]
5. Dilated fundus examination. After eye drops enlarge the pupils, the doctor looks at the retina and optic nerve. In cone-rod degeneration, the macula may show atrophy, pigment changes, or other retinal abnormalities, although early disease can look subtle. [Review article]
6. Color vision testing. Tests such as Ishihara or more detailed color plates can show poor color discrimination. This is very useful because color vision problems are common early signs of cone dysfunction. [NCBI Bookshelf]
7. Contrast sensitivity testing. This checks how well a person can detect faint differences between light and dark. It may show functional loss even when standard letter testing does not fully explain the patient’s complaints. [Approach to IRD]
8. Visual field testing. Automated perimetry or similar field tests measure central and side vision. Cone-rod degeneration may show a central scotoma early and broader field loss later. [IOVS summary]
9. Dark adaptation testing. This measures how the eyes adjust in darkness. It can help show later rod involvement when a patient reports poor vision at night. [Webvision electrophysiology review]
10. Low-vision functional assessment. This practical test checks reading, mobility, glare problems, and daily visual tasks. It does not prove the disease by itself, but it helps document real-life disability and support rehabilitation planning. [Approach to IRD]
11. Genetic testing panel. A blood or saliva sample can be used to look for gene variants known to cause inherited retinal disease. This helps confirm the diagnosis, explain inheritance, and sometimes identify eligibility for research or treatment trials. [AAO guidance; MedlinePlus Genetics]
12. Family segregation testing. Sometimes doctors test parents, brothers, sisters, or other relatives to see how a gene variant runs in the family. This can help decide whether a result is truly disease-causing. [MedlinePlus Genetics]
13. Targeted molecular confirmation. If one specific gene is suspected, such as ABCA4 or CRX, doctors may order confirmatory molecular testing focused on that gene. This is especially useful when the clinical pattern strongly matches a known subtype. [MedlinePlus Genetics]
14. Full-field electroretinography (ffERG). This is one of the most important tests. It records the retina’s electrical response to flashes of light. In cone-rod degeneration, cone responses are reduced first, and rod responses may later also become abnormal. [AAO; Webvision; review]
15. Photopic ERG. This part of ERG measures cone function under light-adapted conditions. It is especially helpful because cone disease is the first major problem in this disorder. [Webvision]
16. 30-Hz flicker ERG. This is another cone-weighted ERG response. It is often reduced or delayed when cone pathways are damaged. [Webvision]
17. Scotopic ERG. This measures rod function in dark-adapted conditions. It may be near normal early, then worsen later as the disease progresses from cone-dominant to cone-rod involvement. [Webvision; review]
18. Multifocal ERG (mfERG). This test measures electrical function from many small central retinal areas at once. It is useful when doctors want to study the macula and central cone function in more detail. [AAO guidance]
19. Optical coherence tomography (OCT). OCT takes cross-sectional pictures of the retina. It can show thinning of the outer retina, damage in the photoreceptor layers, and loss of normal macular structure. This is one of the most useful imaging tests for inherited retinal disease. [IRD review; imaging review]

Non-pharmacological treatments (Therapies and others)

1. Low-vision rehabilitation
Low-vision rehabilitation is a structured program with an eye-care team that teaches you how to use the vision you still have. The team may include optometrists, occupational therapists, and mobility trainers. They show you special reading methods, lighting setups, and tools so that you can keep reading, writing, cooking, and moving around more safely. The purpose is to stay independent in daily life. The main mechanism is learning practical skills, not changing the eye itself. It helps your brain and habits adjust to the reduced vision.

2. Optical magnifiers and reading devices
Handheld magnifying glasses, stand magnifiers, high-power reading glasses, and electronic video magnifiers can make text larger and clearer. The purpose is to help with reading, writing, and seeing small details like medication labels or schoolwork. These tools work by increasing the size and contrast of what you see, so fewer and stronger cone cells can still read the image. Many people with cone-rod degeneration use several devices for different tasks at home, school, or work.

3. Electronic low-vision wearables
Special electronic glasses or headsets use cameras and screens to zoom in, boost contrast, and sometimes use voice feedback. Their purpose is to improve seeing faces, TV, or signs in the distance. They work by capturing the surrounding image, processing it with software, and displaying a brighter, sharper picture in front of the eyes. Some devices can highlight edges or darken bright areas, which is especially helpful because cones are damaged and bright light can feel dazzling.

4. Tinted lenses and sunglasses
Strong sunglasses and tinted lenses (amber, brown, or special filters) reduce glare and light sensitivity. Their purpose is to make bright outdoor or indoor lighting more comfortable and to improve contrast. They work by blocking certain wavelengths of light and reducing overall brightness. This helps damaged cone cells work in a more comfortable light range, so vision feels less “washed out.” Using hats with brims outdoors adds extra glare control.

5. Contrast and large-print strategies
Simple changes at home, like using bold black pens, large-print books, high-contrast keyboards, and dark cutting boards under light food, can make daily tasks easier. The purpose is to make objects stand out more clearly against their background. The mechanism is environmental: increasing contrast and font size does not fix the retina but makes it easier for remaining cones and rods to detect shapes and letters. This lowers eye strain and frustration in study and work.

6. Orientation and mobility training
Orientation and mobility specialists teach safe walking with poor side or night vision. Training may include using landmarks, listening skills, and sometimes a long cane. The purpose is to prevent falls and collisions when side vision and rod function are reduced. The mechanism is not medical; instead, it teaches the brain to rely more on hearing, touch, and the remaining central vision, and to plan paths more carefully. This training is very helpful when rod damage leads to tunnel vision or night blindness.

7. School and workplace accommodations
Reasonable adjustments like extra time on tests, sitting near the board, electronic textbooks, screen readers, and zoom software can make study and work manageable. The purpose is to remove barriers caused by low vision, not to give unfair advantages. These changes work by matching the visual demand of tasks to the person’s remaining visual ability, so they can perform tasks at the same level as others. Laws in many countries support such accommodations for people with visual impairment.

8. Screen magnification and accessibility software
Computers, tablets, and phones have built-in tools such as zoom, high-contrast themes, large cursors, and text-to-speech. The purpose is to help with reading, writing, browsing the internet, and social media. They work by enlarging text and icons, simplifying colors, or reading content aloud so that limited cone function is less of a barrier. Learning these settings early can make school and online work much easier over time.

9. Audio books and text-to-speech tools
Audio books, screen readers, and text-to-speech apps turn written text into spoken words. The purpose is to keep learning, reading, and entertainment possible even when printing gets too hard to see. The mechanism is simple: bypassing damaged photoreceptors by using hearing instead of vision. This can reduce eye strain and may allow people with cone-rod degeneration to handle long reading tasks comfortably.

10. Environmental lighting control
Good lighting that is bright but not glaring is crucial. Using adjustable lamps, indirect light, and warm-colored bulbs can help. The purpose is to reduce light sensitivity and improve clarity without causing discomfort. The mechanism is again environmental: carefully controlling brightness and angle so that damaged cones get enough light to function, while avoiding harsh reflections that cause dazzling.

11. Psychological counseling and support groups
Living with a slowly worsening eye disease can cause sadness, anxiety, or fear about the future. Counseling and peer support groups let people share feelings and coping strategies. The purpose is emotional and mental health support. The mechanism is discussion, education, and problem-solving, which help people accept the diagnosis, plan for future vision changes, and feel less alone. This support also helps families learn how to help without being overprotective.

12. Genetic counseling
Genetic counselors explain which gene changes cause cone-rod degeneration in a family, what testing is possible, and what this means for future children. The purpose is to give clear information and support decision-making. The mechanism is education and risk assessment, not changing genes. Knowing the exact gene can also make it easier to join clinical trials for gene therapy in the future.

13. Regular eye-care follow-up
Even though there is no cure, regular visits with a retina specialist or inherited retinal disease clinic are important. The purpose is to monitor vision changes, catch treatable problems early (like macular swelling or glaucoma), and update low-vision strategies. The mechanism is early detection and timely management of complications, which can preserve useful vision longer and maintain quality of life.

14. Blue-light–filtering and anti-reflective coatings
Special coatings on glasses reduce reflections from screens and indoor lights. Blue-light-filter lenses lower certain high-energy wavelengths that can feel harsh to damaged cones. The purpose is to increase comfort and reduce glare. These coatings work by selectively blocking or redirecting light, making the visual experience softer and clearer. For many people with cone-rod degeneration, this makes daily screen use less tiring.

15. Safe-home modifications
Simple changes like removing loose rugs, adding contrasting tape to steps, using motion-sensor night lights, and marking door frames can prevent falls. The purpose is safety as vision declines, especially when rods are damaged and night or side vision is poor. The mechanism is making the environment more visible and predictable, reducing the need for precise vision to move around safely.

16. Braille and tactile skills (if needed)
Not everyone with cone-rod degeneration will need Braille, but learning Braille or other tactile reading methods can be very helpful if vision falls to very low levels. The purpose is to keep reading and learning independent of sight. The mechanism is shifting the main input from vision to touch, allowing education and communication to continue even if the retina can no longer provide useful images.

17. Voice-assistant and smart-home tools
Voice-controlled devices (for example smart speakers, phones, and home assistants) can help with calling people, setting reminders, checking time and weather, and controlling lights or appliances. The purpose is to reduce tasks that require vision. They work by taking spoken commands and giving spoken answers, so you can manage many daily tasks without looking at small screens or buttons.

18. Exercise and general physical activity
Regular, safe exercise (walking, swimming, cycling on a stationary bike) supports heart health and mental health. While exercise does not cure cone-rod degeneration, the purpose is to keep the body and brain healthy and reduce stress. The mechanism is improved blood flow, better sleep, and mood-boosting chemicals in the brain, which help people cope better with a chronic condition.

19. Sleep and daily routine management
Good sleep habits (fixed bedtime, dark quiet room, limiting screens late at night) help reduce fatigue and eye strain. The purpose is to ensure that the brain and eyes are as rested as possible so that remaining vision works at its best during the day. The mechanism is overall nervous-system recovery and better focus, which can make coping with low vision easier.

20. Participation in clinical trials (when available)
Some research studies test new treatments like gene therapy, stem-cell therapy, or new devices for inherited retinal diseases. The purpose is to learn whether new methods are safe and effective. The mechanism depends on the trial (for example, replacing a faulty gene or adding light-sensitive proteins). Clinical-trial participation is strictly controlled; it may help science, but it is not guaranteed personal treatment, and risks must be discussed carefully with the medical team.

Drug treatments (Medicines – supportive, not curative)

There is no medicine that cures cone-rod degeneration or fully stops it. Medicines are mostly used to treat specific problems like cystoid macular edema (swelling in the central retina), high eye pressure, or eye surface discomfort. The drugs below are examples often used in related retinal or glaucoma conditions. Doses are general information only; any real treatment must be decided by an eye specialist who knows the person’s full health history.

1. Oral carbonic anhydrase inhibitor – acetazolamide (Diamox)
Acetazolamide is a pill that blocks the enzyme carbonic anhydrase. It is mainly approved for glaucoma, certain types of edema, and other conditions, but doctors sometimes use it off-label to reduce retinal swelling (cystoid macular edema) in inherited retinal diseases. Typical adult doses in its label are 250–375 mg once or twice daily, in cycles, but dosing is highly individual. It lowers fluid production and can help remove excess fluid from the retina. Common side effects include tingling in fingers and toes, tiredness, frequent urination, and changes in blood salts.

2. Extended-release acetazolamide (Diamox Sequels)
This is a long-acting capsule form of acetazolamide. Its purpose is similar: lowering fluid build-up by blocking carbonic anhydrase, with steadier levels over the day. Label doses often include 500 mg once or twice daily for approved conditions; only an eye specialist or neurologist can decide on off-label use. The mechanism is the same as standard acetazolamide but with slower release. Side effects are similar: tiredness, loss of appetite, stomach upset, kidney stone risk, and changes in blood chemistry, so blood tests and kidney checks are important.

3. Topical dorzolamide eye drops (TRUSOPT)
Dorzolamide 2% eye drops are carbonic anhydrase inhibitors used to lower eye pressure in glaucoma. In some inherited retinal diseases, doctors also use them off-label to reduce cystoid macular edema. A common label dose for glaucoma is one drop three times daily in the affected eye(s). They work by reducing fluid (aqueous humor) production and may also improve fluid pumping in the retina. Side effects can include burning or stinging, bitter taste, and rare allergic reactions to sulfonamides.

4. Dorzolamide–timolol combination eye drops (COSOPT)
This eye drop combines dorzolamide with timolol (a beta-blocker) to lower eye pressure. It is approved for glaucoma but may be used if a person with cone-rod degeneration also has high pressure or glaucoma. Typical labeled dosing is one drop twice daily. The mechanism is dual: less fluid made (dorzolamide) and more fluid drained (timolol effect). Side effects may include eye irritation, slow heart rate, low blood pressure, or breathing problems in sensitive people, so it must be used very carefully.

5. Other topical carbonic anhydrase inhibitors (e.g., brinzolamide)
Brinzolamide eye drops are similar to dorzolamide and are also approved to lower intraocular pressure. In some inherited retinal conditions, they may be tried for macular edema. Typical label dosing is one drop three times a day. They work by blocking carbonic anhydrase in the eye’s ciliary body and possibly helping fluid movement in retinal tissue. Side effects are usually mild burning, blurred vision after drops, or bitter taste but can rarely be more serious.

6. Topical non-steroidal anti-inflammatory drops (e.g., ketorolac)
Ketorolac eye drops reduce inflammation and are mainly approved for post-surgery pain and swelling or for seasonal allergic conjunctivitis, not for cone-rod degeneration. In some cases of retinal swelling, they may be part of combined therapy. Doses often involve one drop four times daily for a limited period. The mechanism is blocking prostaglandins that drive inflammation. Possible side effects are eye irritation, delayed healing if overused, and very rare corneal problems.

7. Topical corticosteroid eye drops (e.g., prednisolone acetate)
Steroid drops reduce inflammation inside the eye. They are sometimes used short-term when there is eye inflammation, but they do not treat the genetic cause of cone-rod degeneration and are not used long-term without a clear reason. Usual eye-drop dosing starts with several times daily and then slowly tapers. They work by strongly blocking inflammatory pathways. Side effects include higher eye pressure, cataract risk, and infection risk, so careful medical supervision is needed.

8. Anti-VEGF injections (e.g., ranibizumab)
In rare cases, people with inherited retinal disease can develop abnormal blood vessels under the retina, similar to wet age-related macular degeneration. Anti-VEGF injections are used inside the eye to shrink these vessels and dry up leakage. Dosing is usually monthly at first, then spaced out. They work by blocking vascular endothelial growth factor (VEGF), which drives new blood vessel growth. Main risks are infection in the eye, small bleeding, or increased pressure, though these are uncommon with proper technique.

9. Anti-VEGF injections (e.g., aflibercept)
Aflibercept is another anti-VEGF drug with similar purpose and mechanism to ranibizumab. It binds VEGF and related molecules, reducing leakage and swelling. Dosing regimens vary but often start with monthly injections, then extend to every two months or longer if the retina stays dry. Side effects and risks are similar to other anti-VEGF agents: transient discomfort, rare infection, and rare systemic effects like increased blood pressure. These injections are only used if imaging shows clear abnormal vessels.

10. Intravitreal corticosteroid implants (e.g., dexamethasone implant)
A tiny steroid implant can be injected into the eye to release dexamethasone slowly over several months. It is used for stubborn macular edema from other causes, and in rare inherited retinal cases when other treatments fail. The purpose is long-term control of swelling. The mechanism is continuous, local anti-inflammatory action. Side effects include cataract progression and raised eye pressure, so frequent checks and sometimes glaucoma drops are required.

11. Lubricating eye drops (artificial tears)
People with low vision may blink differently or work on screens more, causing dry, burning eyes. Artificial tears are simple lubricating drops that soothe the eye surface. They can be used many times a day. The mechanism is adding moisture and stabilizing the tear film to reduce irritation. Side effects are usually mild, like brief blurring right after putting in the drop. Preservative-free drops are preferred for frequent use.

12. Hypertonic saline eye drops or ointment
In some people with corneal swelling, hypertonic saline eye drops or ointment draw extra fluid out of the cornea. The purpose is to clear foggy vision caused by surface swelling, not to treat the retina itself. The mechanism is osmotic: saltier solution pulls water from the cornea. Use is usually a few times a day or at night as an ointment. Side effects are stinging and, rarely, irritation.

13. Oral pain relievers (paracetamol / acetaminophen)
Cone-rod degeneration itself is usually painless, but people sometimes get headaches or eye-strain from heavy visual effort. Simple pain relievers like paracetamol may be used occasionally, at standard over-the-counter doses, for comfort. The purpose is symptom relief only. Mechanism is blocking pain-related chemicals in the brain. Overuse can harm the liver, so doses and frequency must stay within safe limits, following product instructions or a doctor’s advice.

14. Oral non-steroidal anti-inflammatory drugs (NSAIDs)
Occasionally NSAIDs like ibuprofen are used for general aches or pain related to other conditions. They do not treat cone-rod degeneration itself but may help overall comfort. They work by blocking COX enzymes and lowering prostaglandins. Overuse can irritate the stomach, kidneys, or increase bleeding risk, so they must be used with care and medical advice, especially in people who already take other medicines.

15. Glaucoma eye drops (beta-blockers, prostaglandin analogues, etc.)
If someone with cone-rod degeneration also has glaucoma or high eye pressure, standard glaucoma drops may be prescribed. The purpose is to protect optic-nerve health and prevent extra vision loss from high pressure. Mechanisms vary: some reduce fluid production; others increase fluid outflow. Side effects differ by class (for example, beta-blockers can slow heart rate, prostaglandins can darken iris color), so choice must be individual.

16. Antioxidant vitamin combinations (drug-like formulations)
Some products combine vitamins C, E, zinc, copper, and carotenoids in tablet or capsule form, originally studied in age-related macular degeneration. While evidence for cone-rod degeneration is limited, some doctors may consider such formulas for general retinal support. The purpose is to supply antioxidants that may reduce oxidative stress. Side effects can include stomach upset, and high doses of certain vitamins may harm people with specific medical conditions, so they should only be used under medical advice.

17. Allergy eye drops (antihistamine / mast-cell stabilizers)
People with cone-rod degeneration can also have common eye allergies. Antihistamine or dual-action allergy drops relieve itching, redness, and tearing. The purpose is comfort and clearer vision by reducing allergy symptoms. They work by blocking histamine and stabilizing mast cells. Side effects are usually mild, like brief stinging or dry eye. They do not affect the retina or the course of cone-rod degeneration.

18. Short-term sedatives for testing or procedures (if needed)
Sometimes, especially in children, mild sedatives are used during uncomfortable tests or procedures, such as imaging or injections. The purpose is to keep the person calm and still so that the test is safe and accurate. The mechanism is slowing brain activity for a short time. These medicines have risks like breathing depression and must only be used under specialist supervision, in a hospital or clinic setting.

19. Systemic medications for associated conditions
Some people with cone-rod degeneration may have other conditions (for example, autoimmune disease or metabolic problems) that also affect vision. Systemic medicines for those conditions can indirectly protect the eyes by controlling inflammation or metabolic stress. The purpose is whole-body health, which supports eye health. Mechanism and side effects depend on the exact drug, so close coordination between specialists is important.

20. Research medicines in clinical trials
A few medicines and gene-based treatments are being tested for inherited retinal diseases. These drugs are only available in controlled research studies and are not yet standard care for cone-rod degeneration. Their purpose is to test new mechanisms like gene replacement or neuroprotection. The mechanism might involve delivering a healthy gene copy or protecting photoreceptors from cell death. Side effects and benefits are still being studied, so participation requires detailed discussion of risks and close follow-up.

Dietary molecular supplements

(Always talk to your doctor before starting any supplement. Some vitamins in high doses can be harmful.)

1. Lutein
Lutein is a carotenoid found in green leafy vegetables. It collects in the macula and may help protect photoreceptors from light-related damage. Typical supplement doses in studies are around 10–20 mg per day, but individual needs vary. Functionally, lutein acts as a blue-light filter and antioxidant, scavenging harmful free radicals. It does not cure cone-rod degeneration but may support general retinal health alongside a balanced diet. Side effects are rare but very high doses long-term are not well studied in children or teens.

2. Zeaxanthin
Zeaxanthin is closely related to lutein and also builds up in the macula. Supplements often combine lutein and zeaxanthin for macular support. Typical zeaxanthin doses are 2–10 mg daily in adult studies. It functions as an antioxidant and light filter, helping to reduce oxidative stress on cone cells. The mechanism is similar to lutein: absorbing high-energy light and neutralizing free radicals. There is no proof that it stops cone-rod degeneration, but it may help maintain retinal health in general.

3. Omega-3 fatty acids (DHA/EPA)
Omega-3s, especially DHA, are major building blocks in retinal cell membranes. Supplement doses vary, but many products offer 500–1000 mg combined DHA/EPA per day. Their function is to support cell membrane fluidity and reduce inflammation. Mechanistically, omega-3s may help protect photoreceptors by stabilizing membranes and modulating inflammatory pathways. They are not a cure but are often recommended as part of a heart-healthy and eye-friendly diet. Side effects may include mild stomach upset or fishy aftertaste.

4. Vitamin A (within safe limits only)
Vitamin A is essential for the visual cycle. However, in some inherited retinal diseases, high-dose vitamin A can be unsafe, especially when certain genes are involved or when liver disease is present. Any vitamin A supplement must be strictly guided by a specialist. Typical safe multivitamin doses are much lower than older high-dose protocols. Its function is supporting rod and cone pigment regeneration. Mechanism is involvement in forming rhodopsin and cone pigments. Too much can damage the liver and bones, so careful medical supervision is vital.

5. Vitamin C (ascorbic acid)
Vitamin C is a water-soluble antioxidant found in fruits and vegetables. Supplement doses often range from 250–500 mg per day in adults. Its function is neutralizing free radicals and regenerating other antioxidants like vitamin E. Mechanistically, vitamin C may help protect tiny blood vessels and retinal tissue from oxidative stress. It does not treat the gene defect but may support overall eye and general health. High doses can cause stomach upset and, in rare cases, kidney stones.

6. Vitamin E (alpha-tocopherol)
Vitamin E is a fat-soluble antioxidant present in nuts and vegetable oils. Adult supplement doses often range from 100–400 IU per day, but high doses can increase bleeding risk in some people. Its function is protecting cell membranes, including photoreceptor membranes, from oxidative damage. Mechanistically, it interrupts free-radical chain reactions in fatty tissues. Vitamin E alone will not stop cone-rod degeneration, but in balanced doses and with doctor guidance, it can contribute to general antioxidant support.

7. Zinc
Zinc is a trace mineral involved in many enzymes, including some related to vision. Supplements in eye formulas typically provide 25–80 mg of zinc per day for adults, often with copper to prevent deficiency. Its function is supporting antioxidant enzymes and immune function. Mechanistically, zinc may help stabilize photoreceptor cell processes and protect against oxidative harm. Too much zinc can cause nausea, copper deficiency, and immune changes, so medical guidance is essential.

8. Copper (with zinc)
Because high-dose zinc can lower copper, eye formulas usually include a small amount of copper (for example 1–2 mg per day). Copper supports red blood cell production and antioxidant enzyme activity. The mechanism is as a co-factor for enzymes such as superoxide dismutase, which neutralizes free radicals. Copper itself does not directly repair cone-rod degeneration but keeps the body’s antioxidant systems balanced when zinc is used. Too much copper can be harmful, so doses must stay small and supervised.

9. B-complex vitamins (B6, B9, B12)
B vitamins support nerve health and energy metabolism. Typical multivitamins supply modest amounts of B6, folate (B9), and B12. Their function is to help neurons, including retinal cells, maintain healthy metabolism and myelin. Mechanistically, they assist in DNA synthesis and repair, and in lowering homocysteine levels, which can stress blood vessels. They do not cure cone-rod degeneration but may help general nerve and vascular health. Very high doses of some B vitamins can cause side effects, so balance is important.

10. Curcumin or plant-based antioxidants (under medical advice)
Curcumin (from turmeric) and other plant antioxidants are being studied for many inflammatory and degenerative diseases. Supplement doses vary widely and should only be used under medical advice, especially if other medicines are taken. Their function is to reduce oxidative stress and inflammation. The mechanism likely involves multiple cell-signaling pathways. Evidence in cone-rod degeneration is still experimental, so these are best viewed as general wellness supplements, not targeted therapy.

OR

No supplement has been proven to cure cone-rod degeneration. Some are studied in other retinal diseases. Always discuss supplements with your doctor, especially if you are pregnant, have liver disease, or take other medicines.

1. Lutein
Lutein is a carotenoid concentrated in the macula. It helps filter blue light and may reduce oxidative stress in photoreceptors. Supplements often contain 10–20 mg per day, though food sources like spinach and kale are preferred. Mechanism: lutein absorbs high-energy light and neutralizes free radicals. Evidence is strongest in age-related macular degeneration, not cone-rod disease, but it is commonly considered as supportive nutrition.

2. Zeaxanthin
Zeaxanthin sits with lutein in the macular pigment. Typical supplement doses are around 2 mg or more daily. It improves blue-light filtering and may support contrast sensitivity. Mechanism is similar to lutein: antioxidant activity and light filtering. Foods rich in zeaxanthin include corn, orange peppers, and egg yolks.

3. Omega-3 fatty acids (DHA/EPA)
DHA is a major fatty acid in photoreceptor membranes. Omega-3 supplements (often 500–1000 mg or more of combined EPA/DHA daily) may support retinal structure and reduce inflammation. Mechanism includes anti-inflammatory effects and membrane stabilization. Evidence is mixed, but some studies suggest benefits in dry eye and macular diseases. Fish (like salmon, sardines) are natural sources.

4. Vitamin A (low-dose, if safe)
Vitamin A is essential for the visual cycle, but high doses can be toxic. In some RP trials, 15,000 IU/day showed a modest slowing effect, but later work has challenged this and highlighted risks, especially in certain genotypes and during pregnancy. If used at all, dose and safety tests (liver function, vitamin A levels) must be carefully monitored by specialists.

5. Vitamin C and Vitamin E
These antioxidants may help neutralize free radicals in retinal tissue. They are often included in eye vitamin formulas at doses like 500 mg vitamin C and 400 IU vitamin E daily. However, one RP trial suggested that high-dose vitamin E might worsen progression, so uncontrolled high dosing is not recommended. A balanced diet rich in fruits, vegetables, and nuts is safer.

6. Zinc
Zinc is important for many retinal enzymes and has been used in age-related macular degeneration formulas. Typical supplement doses in eye formulas are about 25–80 mg per day, though high doses can upset the stomach and affect copper levels. Mechanism: cofactor in antioxidant enzymes and visual cycle proteins. Its role in cone-rod degeneration is uncertain.

7. Coenzyme Q10 / Idebenone
CoQ10 and its analog idebenone support mitochondrial energy production and act as antioxidants. They have been studied mainly in Leber hereditary optic neuropathy, not cone-rod degeneration. Typical supplement doses vary widely (for example 90–300 mg/day). They may protect cells under oxidative stress, but clear benefit in cone-rod degeneration is unproven.

8. Alpha-lipoic acid
Alpha-lipoic acid is another antioxidant that can regenerate other antioxidants like vitamin C and glutathione. Doses in metabolic studies are often 300–600 mg/day. It may improve blood flow and reduce oxidative damage, but evidence in inherited retinal disease is very limited. It can affect blood sugar, so people with diabetes need medical advice.

9. Resveratrol
Resveratrol, found in grapes and berries, has antioxidant and anti-inflammatory actions in lab studies. Supplement doses vary widely. In retinal cells, it may protect against oxidative stress and apoptosis, but human data are limited. It should not be seen as a treatment; at best it is a possible supportive antioxidant taken after medical advice.

10. Curcumin
Curcumin, from turmeric, has anti-inflammatory and antioxidant properties. In lab models, it may protect retinal cells from oxidative damage. Absorption from the gut is poor unless combined with enhancers like piperine. Doses in supplements vary, and long-term safety at high doses is not fully known. Again, consider it only as part of an overall healthy diet, not a cure.

---

Regenerative, immunity-boosting,” and stem-cell-related drugs

For cone-rod degeneration and other inherited retinal diseases, the main “regenerative” strategies are still in research. They should not be used outside approved trials or regulated treatments.

1. Gene-replacement therapy (e.g., voretigene neparvovec)
Gene therapy delivers a normal copy of a faulty gene to retinal cells using viral vectors (often AAV). LUXTURNA, for RPE65 biallelic retinal dystrophy, is the first FDA-approved product of this type. In principle, similar therapies are being developed for many genes that can cause cone-rod degeneration. The goal is to restore missing proteins and slow or stop photoreceptor death.

2. Experimental gene therapies for other IRDs
Many clinical trials are testing gene therapies for different inherited retinal diseases (for example, AAV-based therapies for various gene defects). These are usually given as a one-time injection under the retina. Immune reactions and surgical risks are important concerns, so patients are chosen carefully and followed closely. These are not general “immune boosters” but targeted genetic treatments.

3. Encapsulated cell therapy with ciliary neurotrophic factor (CNTF, e.g., NT-501)
Encapsulated cell technology implants tiny capsules into the eye that slowly release CNTF, a neurotrophic factor that can support photoreceptors. Studies in retinal degenerative diseases show that long-term CNTF delivery is biologically active and appears safe, and recent reports suggest it may slow degeneration in certain conditions. The mechanism involves activating survival pathways (like JAK/STAT) in retinal cells.

4. Brimonidine neuroprotective implants
Brimonidine is a glaucoma drug with documented neuroprotective effects on retinal cells in lab and animal models. Sustained-release intravitreal implants are being studied to slow geographic atrophy and other retinal degenerations by making retinal pigment epithelial cells and photoreceptors more resistant to injury. The drug activates α2-adrenergic receptors and multiple survival pathways. These implants remain experimental for inherited retinal disease.

5. Stem-cell transplantation
Stem-cell-based therapies aim to replace or support damaged retinal cells using transplanted cells. Early trials in retinitis pigmentosa and Stargardt disease suggest stem cell therapy can be delivered safely and may offer some functional benefit, but evidence is still limited and long-term results are not fully known. Mechanisms include cell replacement, neurotrophic support, and modulation of inflammation.

6. Stem-cell–derived extracellular vesicles / exosomes
Some new trials are testing small vesicles (extracellular vesicles) released from stem cells. These carry proteins and RNA that can alter inflammation and cell survival. They may offer the benefits of stem cells with lower risk of uncontrolled growth. These treatments are at a very early research stage, and no such therapy is approved for cone-rod degeneration yet.

---

Surgeries (Procedures and why they are done)

1. Subretinal gene-therapy injection (e.g., LUXTURNA surgery)
For eligible patients with RPE65-related retinal dystrophy, surgeons perform a pars plana vitrectomy and inject the gene therapy under the retina. This places the vector close to the target cells. The aim is to improve or stabilize functional vision and dark adaptation. This operation is only done in specialized centers and carries risks like retinal tears, infection, and cataract.

2. Encapsulated cell therapy implant surgery (CNTF devices)
In encapsulated cell therapy, a small capsule that continuously releases CNTF is surgically placed in the vitreous cavity. The purpose is long-term delivery of neuroprotective factor to slow retinal degeneration. Surgery is similar to other vitreoretinal procedures and is done under operating-room conditions. This approach is emerging and may not be widely available yet.

3. Cataract surgery
People with long-standing retinal diseases may develop cataracts (clouding of the natural lens). Cataract surgery replaces the cloudy lens with a clear artificial lens. This does not fix cone-rod degeneration but can improve the amount of light reaching the retina and make the best use of remaining cells. The decision to operate depends on cataract severity and expected visual gain.

4. Vitrectomy for complications
If complications like vitreous hemorrhage, epiretinal membrane, or retinal detachment occur, a vitrectomy may be needed. In this surgery, the gel (vitreous) is removed and the retina is repaired. The main goals are to preserve whatever vision is left and prevent further structural damage. Surgeons weigh the benefits against the risk of surgery in already fragile retinas.

5. Low-vision surgical devices (e.g., intraocular telescopes in selected cases)
In very selected adults with severe central vision loss from other retinal diseases, special implants like intraocular telescopes may be used. These are not common in cone-rod degeneration, but conceptually they magnify the image on the retina. Because cone-rod degeneration often affects a wide retinal area, these devices may help only a subset of patients, and careful evaluation is needed.

---

Prevention strategies

Because cone-rod degeneration is usually genetic, it cannot currently be fully prevented. However, you can reduce extra stress on the retina and protect overall eye health:

1. Avoid smoking and vaping – both increase oxidative stress and harm blood vessels.

2. Protect eyes from UV and intense light with good sunglasses and hats.

3. Control systemic diseases such as diabetes, high blood pressure, and high cholesterol.

4. Avoid unnecessary retinal-toxic drugs (for example, high-dose chloroquine/hydroxychloroquine), after discussing options with your doctors.

5. Eat a balanced, nutrient-rich diet full of colorful fruits, vegetables, whole grains, and healthy fats.

6. Maintain a healthy weight and regular exercise routine to support circulation.

7. Have regular eye exams to catch treatable complications early (e.g., macular edema, cataract, glaucoma).

8. Use proper lighting at home and school/work to avoid eye strain and accidents.

9. Seek genetic counseling before planning a family to understand recurrence risk and options.

10. Stay informed about research through trusted organizations and clinics, not unregulated “cures” advertised online.

---

When to see a doctor

You should see an eye doctor (preferably a retina specialist familiar with inherited retinal disease) if you notice:

• New or worsening blurred central vision

• Increasing light sensitivity or color vision changes

• Difficulty seeing at night or frequent tripping in dim light

• Sudden flashes of light, floaters, or a curtain over part of your vision (these may be retinal emergency signs)

• Rapid drop in vision in one or both eyes

Children with possible cone-rod degeneration should be seen early, because timely low-vision support and school accommodations can protect learning and development. Even if nothing can “cure” the disease, regular care helps you get the best out of the vision you still have and keeps you informed about trials and new treatments.

---

What to eat and what to avoid

1. Eat colorful vegetables daily
Dark green leafy vegetables (spinach, kale), orange vegetables (carrots, sweet potatoes), and peppers provide carotenoids and vitamins that support general eye health.

2. Include oily fish several times a week
Salmon, sardines, mackerel, and trout are rich in omega-3 fatty acids that may support retinal cell membranes and reduce inflammation.

3. Choose nuts and seeds as snacks
Almonds, walnuts, and sunflower seeds provide vitamin E, healthy fats, and minerals. In moderation, they may help antioxidant defenses.

4. Eat fruits rich in vitamin C
Citrus fruits, berries, and kiwis bring vitamin C and other antioxidants that support blood vessels and connective tissue in the eye.

5. Drink enough water
Good hydration helps overall body function and keeps the tear film stable, which can improve comfort during reading and screen use.

6. Avoid smoking and tobacco
Tobacco products damage blood vessels and the retina, adding extra risk on top of the genetic disease.

7. Limit highly processed, sugary foods
Large amounts of refined sugar and ultra-processed foods can worsen diabetes and cardiovascular disease, which in turn harm the eyes.

8. Avoid excessive alcohol
Heavy alcohol use can damage the liver and nervous system and may interfere with nutrient absorption, including vitamins important for vision.

9. Be careful with high-dose single-nutrient supplements
Very high doses of single vitamins (especially vitamin A or E) can be harmful and are not proven for cone-rod degeneration. Always ask your doctor before starting them.

10. Discuss any special diets with your care team
If you follow vegetarian, vegan, or other special diets, your doctor or dietitian can help you make sure you still get enough omega-3s, vitamin B12, and other key nutrients for overall health.

---

FAQs

1. Is cone-rod degeneration curable?
No. At this time there is no cure for cone-rod degeneration. Treatments focus on protecting remaining vision, managing complications, and supporting daily life. Gene and cell therapies are under active research, but they are not yet widely available for most forms.

2. Will I go completely blind?
Many people keep some useful vision, especially for movement and shapes, even late in the disease. However, fine central detail and night vision often decline. The exact course depends on your specific gene change. Genetic testing and regular exams can give a more personalized outlook.

3. Can glasses or contact lenses fix cone-rod degeneration?
Regular glasses can correct refractive error (like myopia or astigmatism) but cannot repair damaged retinal cells. However, properly chosen glasses, tints, or contact lenses can reduce glare and make the most of your remaining vision.

4. Is cone-rod degeneration always inherited?
Most cases are genetic and inherited, but the exact pattern (dominant, recessive, X-linked) varies. Rarely, similar patterns of damage may occur from other causes. Genetic testing helps confirm the diagnosis and inheritance pattern.

5. Should my family members be tested?
If a gene change is found in you, relatives may be offered genetic testing and eye exams. This can detect disease early and inform family planning. Decisions about testing are personal and should be made with a genetic counselor.

6. Is it safe to have children?
Many people with inherited retinal disease choose to have children. Genetic counseling can explain the chances that a child will inherit the gene change and what options exist (for example, prenatal or preimplantation genetic testing in some settings).

7. Can I use screens and phones, or do they make my eyes worse?
Screens do not seem to speed up retinal degeneration, but they can cause eye strain and discomfort. Using dark mode, larger fonts, and regular breaks can help. Your doctor or low-vision specialist can adjust settings that work best for you.

8. Are “eye vitamins” from the store helpful?
Some eye vitamin formulas may support general retinal health, but they have not been proven to stop cone-rod degeneration. High doses, especially of vitamin A and E, can be harmful in some people. Always ask your doctor before starting supplements.

9. Will exercise help my vision?
Exercise does not cure retinal degeneration, but it helps your heart and blood vessels, which support the eyes. It also improves mood and overall health. Choose safe activities and discuss any limitations with your doctor.

10. Are there special schools only for visually impaired children?
Depending on your country, there may be specialized schools or mainstream schools with strong support services. Many children with cone-rod degeneration stay in regular schools with accommodations and help from vision teachers.

11. Can I still work if my vision gets worse?
Yes, many people work successfully with support such as screen-reading software, magnifiers, flexible schedules, and job modifications. Early discussion with employers and rehabilitation services is important to arrange these tools.

12. Are online “stem cell cures” safe?
Be very careful. Many clinics sell unproven stem cell injections without proper approval, and serious complications (including blindness) have been reported. Only join treatments that are part of regulated clinical trials or approved therapies advised by your specialist.

13. How often should I see my eye doctor?
Your specialist will choose the interval based on age, symptoms, and disease stage. Many people are seen every 6–12 months, and more often if there is macular edema, glaucoma, or before and after surgery.

14. What research looks most promising?
Active areas include gene therapy, gene editing, neuroprotective drugs (like CNTF and brimonidine implants), and stem cell-based treatments. These are promising but still evolving, and most are not yet routine care.

15. What should I do next if I think I have cone-rod degeneration?
The most important step is to see an eye specialist, ideally a retina or inherited retinal disease expert. They can confirm the diagnosis, arrange genetic testing, and connect you with low-vision services, rehabilitation, and (if appropriate) clinical trials. Do not start high-dose supplements or internet “treatments” on your own.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: March 03, 2025.